Oncology Focused. We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Our primary areas of focus are oncology and hematology.

Financially Strong. We are a publicly traded pharmaceutical company with strong cash reserves and royalty revenues from the sales of our product DACOGEN®. In addition, our partnerships could deliver significant product milestones and future royalties.